Morningstar

Regeneron Pharmaceuticals Inc REGN

Morningstar Rating
Unlock
Stock XNAS Rating as of
$664.52 −3.43 (0.51%)
View Full Chart
As of Delayed Price Pre-Open: $662.31 −2.21

Company Report

View Archive

Regeneron's Portfolio Still Supports a Narrow Moat Despite Competitive Threats to Eylea

Jay Lee

Regeneron has leveraged its monoclonal antibody research and development platform to become one of the few biotechs to be a profitable commercial operation and establish a narrow moat. Lead drug Eylea had global sales of just under $10 billion in 2024 and is approved for wet age-related macular degeneration and other eye-related indications. The majority of sales are for original-dose Eylea, but over the next few years, we expect most of its sales to shift to long-acting Eylea HD, a higher-dose formulation.

Read Full Report

Price vs Fair Value

View History
REGN is trading within a range we consider fairly valued.
Price
$664.52
Fair Value
LOCK|X!
Uncertainty
LOCK|kKVj
1-Star Price
LOCK|Z.x
5-Star Price
LOCK|Sz
Economic Moat
LOCK|bbV<?
Capital Allocation
LOCK|F^<?F>H

Bulls Say, Bears Say

Bulls

Eylea HD is one of the leading franchises in wet AMD and other ophthalmology markets, with Roche's Vabysmo as its main competitor.

Bears

Regeneron's pending application for US approval of Eylea HD's prefilled syringe is important for its market share.

Show More

News

View All

Articles & Videos

Trading Information

Previous Close Price
$667.95
Day Range
$658.50–676.66
52-Week Range
$541.00–821.11
Bid/Ask
$655.45 / $675.40
Shares Outstanding
104.84M
Market Cap
$69.67B
Volume/Avg
108 / 999,141

Key Statistics

Price/Earnings (Normalized)
14.53
Price/Sales
4.79
Dividend Yield (Trailing)
0.55%
Dividend Yield (Forward)
0.57%
Total Yield
4.93%

Company Profile

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Value
Total Number of Employees
15,410
Website
https://www.regeneron.com

Competitors

Valuation

View More
Metric
REGN
RHHBY
NVS
Price/Earnings (Normalized)
 14.5316.2717.85
Price/Book Value
 2.227.727.69
Price/Sales
 4.794.365.32
Price/Cash Flow
 15.6114.3015.22
Price/Earnings
REGN
RHHBY
NVS

Financial Strength

Metric
REGN
RHHBY
NVS
Quick Ratio
 2.841.100.53
Current Ratio
 3.571.380.85
Interest Coverage
 93.3013.4613.66
Quick Ratio
REGN
RHHBY
NVS

Profitability

Metric
REGN
RHHBY
NVS
Return on Assets (Normalized)
 12.66%15.77%15.46%
Return on Equity (Normalized)
 16.34%49.73%39.95%
Return on Invested Capital (Normalized)
 13.26%23.68%22.43%
Return on Assets
REGN
RHHBY
NVS

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|Xl#>>hLOCK|$$$bg$123B
 argenx SE ADR
ARGX
LOCK|jh#&wz?LOCK|hrq$54B
 Alnylam Pharmaceuticals Inc
ALNY
LOCK|!C^b!<LOCK|ZMP!$40B
 BeOne Medicines Ltd ADR
ONC
LOCK|!YbnV@LOCK|v>q$36B
 Moderna Inc
MRNA
LOCK|fQ?>&NLOCK|^$$27B
 Royalty Pharma PLC Class A
RPRX
LOCK|Rb@yRhPLOCK|VD!!d$25B
 Incyte Corp
INCY
LOCK|!g@f<xKLOCK|$hf$23B
 BioNTech SE ADR
BNTX
LOCK|QMZf!#LOCK|T#M$23B
 BridgeBio Pharma Inc
BBIO
LOCK|<^#$q<nLOCK|%G!$17B

Sponsor Center